drugset / Trial / NCT02408731

A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers

NCT02408731 ↗

Phase 1 Completed 24 enrolled Pharmazz, Inc.
RandomizedSingle-groupTriple-blindTreatment

Summary

Shock is a condition of reduced tissue perfusion, resulting in the inadequate delivery of oxygen and nutrients that are necessary for cellular function. The current resuscitative agents can extend patient's life to a limited extent. Centhaquin (PMZ-2010) in very low doses reduced blood lactate levels, improved blood pressure, cardiac output, survival and proved to be a highly effective resuscitative agent. The investigators are conducting a phase I clinical study in humans to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of centhaquin citrate in normal healthy volunteers.

Timeline

Start
2014-10
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Centhaquin Unknown 0.005 mg/kg Intravenous
Subject Centhaquin Unknown 0.01 mg/kg Intravenous
Subject Centhaquin Unknown 0.05 mg/kg Intravenous
Subject Centhaquin Unknown 0.1 mg/kg Intravenous

Indications

No indication recorded.